Sanofi(US:SNY) 智通财经网·2025-12-17 13:16Core Viewpoint - Sanofi (SNY.US) announced the approval of Aficamten (Chinese trade name: 星舒平), a second-generation cardiac myosin inhibitor, by the National Medical Products Administration for the treatment of adults with obstructive hypertrophic cardiomyopathy (HCM) classified as NYHA functional class II-III, aimed at improving exercise capacity and symptoms [1] Group 1 - Aficamten is a small molecule cardiac myosin inhibitor developed by Cytokinetics, designed to improve the therapeutic index and pharmacokinetic characteristics through comprehensive chemical optimization [1] - The drug reduces the number of active myosin cross-bridges per heartbeat, thereby inhibiting excessive myocardial contraction associated with hypertrophic cardiomyopathy [1] - Aficamten has a short half-life of only 3-4 days and can reach optimal dosing within 8 weeks [1] Group 2 - In 2020, Cytokinetics granted an exclusive license to Jiseng Pharmaceutical for the development and commercialization of Aficamten in the Greater China region [1] - In 2024, Sanofi will acquire the exclusive development and commercialization rights for Aficamten in Greater China from Jiseng Pharmaceutical [1] - Aficamten is considered a potential "best-in-class" treatment in the field of hypertrophic cardiomyopathy, and its approval marks the "global first launch" of this innovative drug in China, ahead of approvals in the US and EU [1]